Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on June 5 at an average price of $547.62, generating about $5.2 million in proceeds. After the sale, she directly owned 40,513 shares, a 19% reduction in her holdings.
- The company recently missed earnings expectations, reporting $5.82 EPS versus the $7.00 consensus estimate, while revenue of $781.5 million also came in below forecasts. Revenue fell 1.6% year over year in the quarter.
- Wall Street remains broadly positive on UTHR, with 11 analysts rating it a Buy and two a Hold, and a consensus price target of $619.42. Several firms also recently raised their targets, including Wells Fargo, which upgraded the stock to Overweight.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,729.06. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
United Therapeutics Stock Performance
UTHR stock opened at $544.69 on Tuesday. The stock has a market cap of $23.12 billion, a P/E ratio of 20.11, a P/E/G ratio of 1.79 and a beta of 0.57. The firm has a 50 day simple moving average of $568.47 and a 200 day simple moving average of $519.64. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.63 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 26.84 EPS for the current year.
Institutional Investors Weigh In On United Therapeutics
Several large investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC boosted its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Wellington Management Group LLP increased its position in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its position in shares of United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock worth $624,508,000 after purchasing an additional 295,221 shares during the period. Janus Henderson Group PLC increased its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock worth $514,016,000 after purchasing an additional 70,829 shares during the period. Finally, Darwin Global Management Ltd. bought a new position in shares of United Therapeutics in the third quarter worth $317,617,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently commented on UTHR. HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a research report on Tuesday, March 31st. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America boosted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research note on Tuesday, March 31st. Jefferies Financial Group reiterated a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $619.42.
Check Out Our Latest Stock Analysis on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
